ArticleSleep & breathing = Schlaf & Atmung2023
Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction.
Article in Sleep & breathing = Schlaf & Atmung, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.
- Investigating the effect of valsartan/sacubitril on sleep parameters of patients with sleep apnea: systematic review and meta-analysis.Sleep & breathing = Schlaf & Atmung · 2026Pooled it
- Impact of sacubitril/valsartan on chronic heart failure patients with sleep-disordered breathing: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Construction and evaluation of a predictive model for the types of sleep respiratory events in patients with OSA based on hypoxic parameters.Sleep & breathing = Schlaf & Atmung · 2024Article
- CPAP Treatment at Home after Acute Decompensated Heart Failure in Patients with Obstructive Sleep Apnea.Journal of clinical medicine · 2024Article
- Impact of sacubitril/valsartan on cardiac and systemic hypoxia in chronic heart failure.iScience · 2024Article
- Association between Obstructive Sleep Apnea and Heart Failure in Adults-A Systematic Review.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the effect of sacubitril-valsartan (SV) on central apneas (CA) and obstructive apneas (OA) in patients with heart failure with reduced ejection fraction (HFrEF).
methodsIn patients with HFrEF, SV initiation was titrated to the highest tolerable dosage. Patients were evaluated with portable apnea monitoring, echocardiography, and cardiopulmonary exercise testing at baseline and 3 months later.
resultsOf a total of 18 patients, 9 (50%) had OA, 7 (39%) had CA, and 2 (11%) had normal breathing. SV therapy was related to a reduction in NT-pro BNP and an improvement in LV function after 3 months. Portable apnea monitoring revealed a significant decrease of the respiratory event index (REI) after treatment with SV (20 ± 23 events/h to 7 ± 7 events/h, p = 0.003). When subgrouping according to type of apneas, REI, and time spent below 90% saturation (T90) decreased in patients with CA and OA (all p < 0.05).
conclusionIn this prospective study, SV treatment for 3 months in patients with CA and OA is associated with a significant decrease in REI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.